At both time points, a higher proportion of patients showing ≥5 CTCs and CTC-clusters was found in the HR+HER2- subtype, however, we did not find significant differences on the distribution in relation to BC subtype at baseline and follow up (Table S2). This evidence concerns the gene ERBB2 and breast cancer.